Trends in Osteoporosis Drug Therapy Receipt Among Commercial and Medicare Advantage Enrollees in the United States, 2011-2022
Authors' conclusion
ODT use for patients with documented osteoporosis has increased but remains low. Low rates of ODT use for patients with fragility fractures in the absence of documented osteoporosis suggests that underdiagnosis of osteoporosis contributes to underuse of ODTs.
Study context
- Population
- Adults aged ≥50 years with commercial or Medicare Advantage insurance, OptumLabs Data Warehouse, 2011–2022
- Participants
- 166,673,420 patient-quarter observations
- Outcome
- Proportion of patient-quarter observations with ODT use, stratified by age, sex, fragility fracture and documented osteoporosis
- Follow-up
- 2011–2022
Methodological detailspatient-quarter observations, Cuzick trend tests
- Patient-quarter observations
- Cuzick trend tests
Main finding
As reported in the abstract
ODT fill rates, women aged ≥65 years · 2011 to 2022
- Documented osteoporosis, no fragility fracture: increased 36.3% to 50.1%
- P < .001
- Documented osteoporosis, with fragility fracture: increased 30.8% to 43.7%
- P < .001
- Fragility fracture, no documented osteoporosis: declined 9.2% to 7.4%
- P = .015
Observational data: associations, not effects.
Further findings
Documented osteoporosis among patients with fragility fractures
- Patients with fragility fractures without documented osteoporosis
- over 70%
Osteoporosis drug therapy (ODT) trends, women aged 50-64 years and men
- Similar trends observed among women aged 50-64 years and men
Original publication
Trends in Osteoporosis Drug Therapy Receipt Among Commercial and Medicare Advantage Enrollees in the United States, 2011-2022. J Clin Endocrinol Metab. Published 15 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →